78,557 Shares in Altimmune, Inc. (NASDAQ:ALT) Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 78,557 shares of the company’s stock, valued at approximately $332,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.16% of Altimmune as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Tekla Capital Management LLC purchased a new stake in Altimmune in the first quarter valued at approximately $316,000. Bank of New York Mellon Corp raised its stake in shares of Altimmune by 10.6% during the first quarter. Bank of New York Mellon Corp now owns 58,954 shares of the company’s stock worth $249,000 after purchasing an additional 5,662 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Altimmune during the first quarter worth approximately $138,000. Pitcairn Co. purchased a new stake in shares of Altimmune during the first quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Altimmune during the first quarter worth approximately $88,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ALT shares. HC Wainwright cut their price target on Altimmune from $50.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, August 14th. B. Riley dropped their price objective on Altimmune from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Altimmune Stock Performance

ALT stock opened at $2.40 on Friday. Altimmune, Inc. has a 1 year low of $2.39 and a 1 year high of $23.49. The firm has a market cap of $126.46 million, a P/E ratio of -1.47 and a beta of -0.09. The stock has a 50-day simple moving average of $3.21 and a 200-day simple moving average of $5.55.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.